Evidence map›Paper›PMID 30256563›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2018

Cytotoxicity Enhancement of Paclitaxel by Loading on Stearate-g-dextran Micelles on Breast Cancer Cell Line MCF-7

Fatemeh Ghaffari, Maryam Bahmanzadeh, Amir Nili-Ahmadabadi, Farzin Firozian

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Fatemeh GhaffariDepartment of Biology, College of Basic Science, Hamedan Branch, Islamic Azad University, Hamedan Branch, Hamedan, Iran. Email: ffirozian@yahoo.com
Maryam Bahmanzadeh
Amir Nili-Ahmadabadi
Farzin Firozian
Hamedan University of Medical Sciences · IRHamedan University of Technology · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Paclitaxel (PTX) is a chemotherapeutic agent used for treating breast cancer. The study aimed to prepare PTX loaded dextran stearate (Dex-SA) and evaluate its efficacy against human breast cancer cell line MCF-7. Methods: Dex-SA/PTX micelles were prepared by dialysis method. The micelles size, zeta potential and particle size distribution were measured by dynamic laser light scattering method. Amount of loaded PTX on the polymer measured by HPLC. Release profiles of the drug from the micelles were obtained in buffer (phosphate pH=7.4). Then the cytotoxicity of blank micelles, Dex-SA/PTX micelles and free PTX were evaluated in the MCF-7 cells by MTT method. Result: Loading efficiency of PTX on the Dex-SA was measured about 84.24±9.07%. The smallest particles size was about 193.9±7.1 nm but the other formulation with larger particle size had better zeta potential (-33.5±6.74 mV). The drug release from the micelles was slowly and reached steady state after about 12 hours. The cytotoxicity experiment showed that Dex-SA/PTX micelles have more cytotoxicity compared to free PTX against MCF7 cell lines. Conclusions: Dex-SA polymeric micelle is a suitable carrier for hydrophobic cytotoxic drugs such as PTX.

Indexed as

MicellesAntineoplastic Agents, PhytogenicApoptosisBreast NeoplasmsCell ProliferationDextransDrug LiberationFemaleHumansPaclitaxelPolymersStearatesTumor Cells, CulturedAntineoplastic Agents, PhytogenicDextransMicellesPaclitaxelPolymersStearatesDextran StearateMCF-7PaclitaxelPolymeric Micelles

Identifiers

PMID30256563
PMCPMC6249484
OpenAlexW2890197668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.